Vertex’s $10 Billion Crinetics Takeover Signals Pharma’s Biggest Rare Disease Bet Yet
Vertex Pharmaceuticals is making its largest acquisition ever, placing a massive $10 billion bet on rare endocrine diseases with the purchase of Crinetics Pharmaceuticals. The deal marks a major strategic shift for

Follow